Immix Biopharma (NASDAQ: IMMX)

Last close As at 06/10/2025

USD2.25

0.19 (8.98%)

Market capitalisation

USD60m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Flash

Immix Biopharma — NEXICART-2 enrolment progressing well

Healthcare | Update

Immix Biopharma — Fleshing out the CAR-T strategy

Healthcare | Comment

Immix Biopharma (NASDAQ: IMMX) – Potential to expand NXC-201

Scientist using protective robber gloves for handling substances and experiments

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free